| abstract |
A liquid composition, preferably an oral composition having improved stability comprising a pharmaceutical asset, solvent for solubilizing the aforementioned asset and a chelating agent that is present in a phase of the composition other than the phase of the composition containing the active before mentioned. A liquid composition, preferably an oral composition having improved stability comprising a pharmaceutical asset, solvent for solubilizing the aforementioned asset, chelating agent and reducing agent having an Electrode Potential E value greater than -0.119V, preferably of - O.119V at + 0.250V, approximately A liquid composition, preferably an oral composition having improved stability comprising a pharmaceutical active, solvent for solubilizing the aforementioned active, chelating agent present in a phase of the composition other than that which contains the aforementioned asset and reducing agent having a value of Electrode Potential E ° greater than -0.119V, preferably from 0.119V to + 0.250V, approximately.The composition according to Claims 1, 2 and 3 wherein the chelating agent and the reducing agent are active on a pH scale between 5 to 12 and in aqueous solvent compositions and Non-aqueous.The composition according to Claim 1 to 4 wherein the chelating agent is selected from the group consisting of disodium and calcium salts of tetrasodium ethylenediaminetetraacetic acid (EDTA), sodium hexametaphosphate (SHMP), citric acid, phosphoric acid, Di (hydroxyethyl) glycine, 8-hydroxyquinoline, and mixtures thereof, preferably a calcium or sodium salt of ethylenediaminetetraacetic acid (EDTA) .The composition according to Claim 1 to 5 wherein the level of chelating agent is 0.005% to 1,000%, preferably of 0.050% to 0.150%, and more preferably 0.300% to 0.010%, by weight of the composition. |